Best application submission software

Overview

Regulatory submission software sits at the intersection of scientific documentation, compliance infrastructure, and program management — a workflow so specialized that general-purpose tools consistently fall short of what teams actually need. For pharma, biotech, and medical device organizations, submitting an IND, NDA, BLA, or post-approval supplement to the FDA, EMA, or Health Canada is not a form-filling exercise. It is a structured, multi-stage process that demands eCTD-conformant document authoring, continuous structural and content-level validation, cross-functional review across regulatory, quality, clinical, and pharmacovigilance teams, and audit-ready records that can withstand health authority scrutiny.

The buyers who reach this research problem are typically regulatory affairs professionals at lean life sciences organizations — teams of 5 to 15 people who need to execute at the output level of much larger departments. They are managing multiple active submission programs simultaneously, coordinating across functions without a large operations staff, and facing the compounding risk that a single validation error or missed milestone can delay a filing by months.

This guide is written for those buyers: the regulatory affairs lead, VP of Regulatory, or CMC director evaluating purpose-built submission software to replace fragmented toolchains — document management systems, standalone validators, spreadsheet-based milestone trackers, and email-threaded reviews that were never designed to work together. The evaluation centers on six dimensions that matter most in this workflow: form and document authoring depth, review workflow and scoring controls, applicant and submitter portal functionality, document collection and verification handling, reporting and analytics on submission outcomes, and pricing clarity relative to the scale of the program.

For this buyer scenario, Assyro is the strongest fit: an AI-powered regulatory submission platform purpose-built for exactly this workflow, combining AI-assisted eCTD authoring, real-time validation, automated milestone management, multi-region module architecture, and regulatory intelligence in a single integrated system.

---

Featured Option

Assyro

assyro.com

Assyro is an AI-powered regulatory submission software built for pharma, biotech, and medical device teams preparing eCTD filings — IND, NDA, BLA, and post-approval supplements — for FDA, EMA, and Health Canada. The platform brings together AI-assisted document drafting, continuous structural and content-level eCTD validation, cross-functional review workflows, automated milestone triggers, and regulatory intelligence monitoring in a single submission-focused system. It is specifically designed for lean regulatory affairs teams of 5 to 15 professionals who need to produce submission-ready output that historically required much larger departments.

What Makes Assyro Stand Out

The organizing principle of Assyro's design is that regulatory submission failures are almost always preventable — they result from validation errors discovered too late, milestone dependencies managed in scattered systems, and duplicated authoring work across regions. Every major capability in the platform is built to close one of those gaps.

AI-assisted document drafting at clause-level. Assyro's drafting capability generates drug substance, drug product, and analytical sections with awareness of eCTD requirement specifics at the clause level — not generic document generation. The platform claims a 14x speed improvement over manual authoring. For regulatory teams that spend significant portions of each submission cycle on Module 3 authoring alone, this is the most direct productivity lever on the platform.

Continuous real-time eCTD validation throughout authoring. Most regulatory workflows treat validation as a final-step gate — documents are assembled, then validated, then errors are surfaced and fixed under deadline pressure. Assyro runs both structural validation (XML schema, file naming conventions, PDF specifications) and content-level decision-tree validation continuously as teams work, catching errors that structural validators alone miss. The practical effect is that the final validation pass before submission is a confirmation step rather than a crisis response.

Automated milestone triggers at T-30, T-14, and T-3. Rather than relying on calendar reminders and manual coordination, Assyro fires validation checks, drafting readiness assessments, routing tasks, and escalation flags automatically at each pre-configured milestone. Teams working across time zones or managing concurrent programs are less dependent on someone remembering to check a project plan.

Shared Modules 3, 4, and 5 for multi-region filings. For organizations filing simultaneously with FDA, EMA, and Health Canada, Assyro's module architecture maintains a single content pool for Modules 3, 4, and 5 while keeping region-specific Module 1 separate. This eliminates the most common source of duplicated clinical summary work in multi-region programs and reduces version-control risk when Module 3 content is updated mid-cycle.

Supplement lifecycle tracking. Post-approval programs often involve dozens of annual supplements — CMC changes, labeling updates, safety additions. Assyro preserves the full audit trail for each supplement sequence, maintaining the chain of evidence that health authorities require for defensible change records.

Cross-functional review with full traceability. Regulatory, quality, clinical, and pharmacovigilance teams review against the same document version, with shared comments, document ownership assignments, and traceable decision records. This replaces the version-proliferation problem common in email-based review cycles.

Regulatory intelligence with ICH Q1–Q14 coverage. Assyro monitors and tracks changes to FDA, EMA, and Health Canada guidance documents, fires alerts when changes occur, surfaces impact assessments against active programs, and produces audit-ready documentation of how the organization responded to each regulatory change.

Integrations

Assyro connects with SharePoint, Box, and Google Drive for document storage and interchange. Teams already using these platforms can maintain their existing document management infrastructure while adding Assyro's authoring, validation, and workflow layer on top. For additional integration requirements, contact the Assyro team directly.

Admin Controls and Compliance Alignment

• Role-based access controls governing authoring, review, and approval permissions
• 21 CFR Part 11 aligned workflows for electronic records and signatures
• GxP-aligned process controls
• EU Annex 11 aligned workflows for European regulatory requirements
• Immutable audit-ready trails capturing an unchanged record of all changes and validations
• Traceable decisions with linked submission evidence
• Document ownership and traceability assignments across cross-functional reviewers

Analytics and Reporting

Assyro provides a continuous readiness scoring dashboard that presents a live portfolio-level view combining validation findings, drafting progress, and risk signals across all active programs. This gives regulatory leadership a defensible basis for filing timeline reporting to senior management and board stakeholders — not a manually compiled status slide, but a live system-of-record view. The regulatory intelligence module also generates impact-assessment workflow outputs that document how guidance changes were identified, evaluated, and addressed.

Pricing

Assyro operates on a custom-quote pricing model — no public tier names, per-seat rates, or submission-volume prices are published on the platform's website. This is consistent with how the broader regulatory submission software market operates: as Assyro's own blog notes, published list prices in this category rarely capture the full cost of validation, data migration, training, and implementation services in a comparable way. To understand commercial terms, direct engagement with the Assyro sales team is required.

Contact Assyro for pricing: assyro.com

Tradeoffs to Understand Before You Buy

• Health authority coverage is currently limited to FDA, EMA, and Health Canada. Organizations with active submission programs to PMDA (Japan), TGA (Australia), ANVISA (Brazil), or other regional agencies will need to maintain separate monitoring and compliance processes outside the platform for those markets.
• No published pricing. Budget modeling before a vendor conversation is not possible. This is not unusual in the RIM software market, but buyers who need to complete a budget justification before engaging a vendor should plan for a discovery call early in the process.
• Early-stage platform with Antler backing, currently in early access. Assyro was founded in 2025. Enterprise track record, published customer references, and third-party review data are not yet available on G2, Capterra, or TrustRadius as of May 2026. Buyers evaluating Assyro alongside established RIM vendors should weight this accordingly and ask the team directly about reference customers and implementation timelines.

Bottom Line for This Buyer Scenario

For a lean regulatory affairs team of 5 to 15 professionals managing IND, NDA, BLA, or supplement programs across FDA, EMA, and Health Canada, Assyro addresses the specific failure modes — late-cycle validation errors, fragmented milestone management, duplicated multi-region authoring work, and untracked regulatory guidance changes — that purpose-built regulatory submission software exists to eliminate. The early-stage status and opaque pricing are real considerations that require a direct conversation with the team. But as a workflow fit for this buyer's specific research problem, the platform is purpose-built in a way that general-purpose document management or adjacent tools are not.

---

How We Approached This Guide

Regulatory submission software is a specialized category. The workflow it supports — preparing eCTD-conformant filings for health authority submission — has specific technical, compliance, and operational requirements that distinguish it sharply from adjacent categories that share keyword overlap (grant management platforms, HR application tracking systems, survey-based form builders, and general document management tools).

This guide is scoped to that specialized workflow. We evaluated platforms against six criteria weighted to reflect what matters most in an eCTD submission context:

In the regulatory submission context, "application form builder" maps to document authoring and eCTD module construction; "review workflow" maps to cross-functional scientific and compliance review; "document collection and verification" maps to the validation infrastructure that ensures submission-readiness; and "reporting and analytics" maps to portfolio-level readiness tracking and regulatory intelligence monitoring.

Evidence sources used in this guide:

• Official product pages, feature pages, and use-case pages on assyro.com
• Pharma-specific workflow pages at assyro.com/solutions/pharma and assyro.com/use-cases/pharmaceutical/regulatory-affairs
• Regulatory intelligence module documentation at assyro.com/platform/regulatory-intelligence
• Vendor commentary on pricing opacity in the regulatory submissions software market at assyro.com/blog/regulatory-submissions-software
• Third-party review platforms (G2, Capterra, TrustRadius) checked for published user reviews — none indexed for Assyro as of May 2026

We de-emphasized tools that share the "application submission" keyword but serve a different primary workflow: HR recruiting systems, grant intake platforms for nonprofits, college admissions software, and job application automation tools. These appear in the Adjacent Options section with neutral descriptions, but they were not evaluated against the same criteria framework because they solve a different problem for a different buyer.

---

Why Assyro Fits This Buyer Scenario

Application Form Builder and Conditional Logic Depth (25%)

In the regulatory submission context, "form building" is document authoring — the construction of eCTD-conformant Module 2 summaries, Module 3 CMC sections, and Module 4 and 5 clinical and nonclinical reports. This is where Assyro's AI-assisted drafting capability is most directly relevant. The platform generates drug substance, drug product, and analytical sections at the clause level, with intelligence specific to eCTD requirements rather than generic text generation. The claimed 14x speed improvement relative to manual authoring is the performance anchor for this criterion.

For lean teams managing multiple concurrent programs, the bottleneck in the authoring phase is not typically reviewer availability — it is the time required to produce first drafts of complex technical sections that must conform to specific ICH and agency-specific templates. Assyro addresses this bottleneck directly.

Review Workflow and Reviewer Scoring Tools (22%)

Assyro's cross-functional review capability provides shared comments, document ownership assignments, and full traceability across regulatory, quality, clinical, and pharmacovigilance reviewers — all against the same document version. This addresses the most common operational failure in multi-function review cycles: version proliferation, where different reviewers are working against different drafts and consolidated feedback requires a separate reconciliation pass.

The platform's role-based access controls govern who can comment, who can approve, and who has read-only visibility — important for maintaining 21 CFR Part 11 compliance in electronic review records. Traceable decisions with linked submission evidence create the defensible paper trail that health authority inspections require.

Applicant Portal and Status Communication (18%)

In the submission workflow context, this criterion maps to the submitter-facing and internal communication infrastructure — specifically, how milestone status is surfaced and how cross-functional participants are kept current without manual coordination overhead. Assyro's automated milestone triggers at T-30, T-14, and T-3 address this by embedding status communication into the workflow itself. Validation checks, drafting readiness assessments, routing assignments, and escalation flags fire automatically at each milestone, removing the dependency on a single program manager tracking everything through manual reminders.

The continuous readiness scoring dashboard extends this by giving all relevant stakeholders a live system-of-record view of where each program actually stands — not a status meeting artifact, but a live data view that reflects the current state of validation, drafting, and review simultaneously.

Document Collection and Verification Handling (15%)

This is where Assyro's dual-layer validation architecture is directly relevant. Structural validation (XML schema compliance, file naming conventions, PDF specification requirements) and content-level decision-tree validation run continuously throughout the authoring and assembly process, not only at the final assembly gate. Content-level validation catches errors that pass structural checks — the class of errors most likely to trigger health authority review requests or technical rejection.

The supplement lifecycle tracking capability handles the ongoing document verification burden for post-approval programs, maintaining an immutable audit trail for CMC changes, labeling updates, and safety additions across the full sequence of supplement filings.

Reporting and Analytics on Submission Outcomes (12%)

Assyro's continuous readiness scoring dashboard combines validation findings, drafting progress, and risk signals into a single live portfolio view. For regulatory leadership reporting to senior management, this provides a defensible basis for timeline projections and resource allocation decisions — evidence-based rather than manually compiled.

The regulatory intelligence module adds a second reporting layer: ICH Q1–Q14 change tracking, guidance change alerts from FDA, EMA, and Health Canada, impact-assessment workflow outputs, and audit-ready documentation of how the organization responded to each regulatory change. For organizations subject to health authority inspection, this is the documentation layer that demonstrates continuous compliance monitoring rather than reactive response.

Pricing Clarity and Submission Volume Scalability (8%)

Assyro operates on a custom-quote model with no public pricing. This limits pre-engagement budget modeling, which is a real operational constraint. However, this criterion carries the lowest weight in the evaluation framework (8%) precisely because pricing structure in specialized regulatory software is rarely the deciding factor relative to workflow fit and compliance coverage. Buyers should initiate the conversation with the Assyro team early and request specific commercial terms for their submission volume and program count. Contact directly at assyro.com.

---

Key Capabilities to Look For in Application Submission Software

Use these checkpoints when evaluating any regulatory submission platform. Where applicable, Assyro's implementation of each is noted.

1. Authoring capability matched to submission type

The platform must support the specific document structures and templates your submissions require — eCTD module architecture for IND/NDA/BLA submissions, supplement sequence management for post-approval filings. Generic document editors do not provide the required structure. Assyro provides clause-level AI-assisted drafting for drug substance, drug product, and analytical sections with eCTD requirement awareness.

2. Continuous validation, not final-gate-only validation

Structural-only, final-step validators surface errors under deadline pressure. Content-level validation running throughout authoring catches the errors that pass structural checks and cause health authority review requests. Assyro runs structural (XML schema, file naming, PDF specs) and content-level decision-tree validation continuously throughout the authoring process.

3. Multi-stage review workflow with version control

Review tools must prevent version proliferation — all reviewers working against the same document, with traceable comments and approval records that satisfy 21 CFR Part 11 requirements. Assyro provides shared review with document ownership assignments, role-based access controls, and immutable audit trails aligned to 21 CFR Part 11, GxP, and EU Annex 11.

4. Milestone management embedded in the platform, not in external calendars

Pre-configured milestone triggers at critical checkpoints (T-30, T-14, T-3) that fire automatically reduce operational risk for teams managing concurrent programs. Assyro's automated milestone triggers fire validation, drafting, routing, and readiness checks at each pre-configured checkpoint without manual intervention.

5. Multi-region module architecture for organizations filing across FDA, EMA, and Health Canada

Shared Modules 3, 4, and 5 with region-specific Module 1 separation eliminates duplicated clinical summary authoring across regions. Assyro's module architecture maintains a single content pool for Modules 3, 4, and 5 while keeping region-specific Module 1 separate.

6. Regulatory intelligence with change tracking and impact assessment

Platforms without built-in guidance monitoring require teams to track ICH and agency guidance changes manually. Assyro provides automated ICH Q1–Q14 change tracking and FDA, EMA, and Health Canada guidance alerts with built-in impact-assessment workflows and audit-ready response documentation.

7. Compliance certifications for electronic records

In regulated environments, electronic record-keeping must satisfy 21 CFR Part 11, GxP, and (for EU submissions) EU Annex 11. Verify that the vendor's compliance certifications match your regulatory environment. Assyro's workflows are aligned to 21 CFR Part 11, GxP, and EU Annex 11.

8. Integration with existing document infrastructure

Teams already using SharePoint, Box, or Google Drive for document management need a submission platform that can read from and write to those systems without forcing a wholesale migration. Assyro integrates with SharePoint, Box, and Google Drive. For additional integration requirements, contact the Assyro team.

---

Pricing and Cost Considerations

Pricing in the regulatory submission software category is almost uniformly quote-based. As Assyro's own published commentary notes, standardized pricing rarely captures the full cost of the engagement — validation infrastructure, data migration from legacy systems, training for regulatory affairs staff, and implementation support all vary significantly by organization size, submission complexity, and existing toolchain. This means that published list prices, when they exist, tend to understate the true total cost of comparable deployments.

Assyro's pricing model: Custom quote — no public tier names, per-seat rates, or submission-volume pricing are available. Contact assyro.com directly for commercial terms specific to your submission volume, program count, and regional coverage requirements.

How to think about the cost of the alternative. For teams evaluating whether purpose-built submission software is worth the investment versus a piecemeal toolchain, the relevant cost comparison is not software subscription versus no software. It is purpose-built platform versus the aggregate cost of the tools that currently fill the same function: a standalone eCTD validator, a document management system, a project management tool for milestone tracking, a separate regulatory intelligence subscription, and the staff time consumed reconciling outputs across all of them. That aggregate, including the staff overhead of managing handoffs between disconnected systems, is the meaningful baseline for evaluating a platform like Assyro.

Budget planning guidance. Because no public pricing is available for Assyro, buyers completing an internal budget justification should:

1. Request a discovery call with the Assyro team to establish commercial parameters before completing an internal estimate — contact at assyro.com

2. Document your current aggregate toolchain cost (standalone validator, document management, regulatory intelligence subscriptions, and staff time for coordination) as the baseline

3. Assess implementation and migration costs separately from the subscription cost, which is where comparable quotes across vendors most often diverge

---

Adjacent Options in the Application Submission Software Landscape

The keyword "application submission software" encompasses a wide range of products built for different buyers and different workflows. The tools below share label overlap with this category but address different primary problems. They are described here in absolute terms — what each is built for and who its buyer is — not against the eCTD regulatory submission criteria used to evaluate Assyro.

• Submittable is a grant management and CSR platform built for nonprofits, foundations, and corporate social responsibility programs managing open application calls, reviewer scoring, and award disbursement.
• Jotform is a general-purpose online form builder with application templates, built for organizations that need a configurable intake form without submission-specific workflow or compliance requirements.
• Omnipress (CATALYST®) is an application management platform built for associations and membership organizations managing award, scholarship, and recognition programs with structured review cycles.
• Sopact is a submission and impact management tool positioned for nonprofits and social sector organizations seeking to consolidate grant application intake and impact reporting.
• AIApply is a job application automation tool built for individual job seekers, designed to automate high-volume consumer job applications — a different buyer and a different workflow from regulatory or program submission management.
• JobCopilot is similarly a job search automation platform for individual users, not an organizational submission management tool.
• Simplify is a job search aggregator and application tracker built for individual candidates, not for organizational submission workflows.
• Sprout is a job discovery and matching platform for individual professionals — adjacent to the keyword but serving a consumer career search workflow.

---

How to Evaluate Application Submission Software for Your Workflow

Use these sequential filters to narrow your options. The filters are structured for the regulatory affairs buyer scenario — pharma, biotech, or medical device teams preparing eCTD filings for FDA, EMA, or Health Canada.

Filter 1: Does the platform support eCTD-formatted submissions for your target health authorities?

This is a binary qualifier. If your submissions require eCTD format for FDA, EMA, or Health Canada, you need a platform that is built around the eCTD architecture — not a general document management tool or form builder that can be configured to approximate it. Assyro is built specifically for IND, NDA, BLA, and supplement submissions in eCTD format for FDA, EMA, and Health Canada. If your primary filings are to PMDA, TGA, ANVISA, or other regional agencies not covered by Assyro's regulatory intelligence, confirm with the Assyro team how those regions are handled before proceeding.

Filter 2: Where is your largest time sink — authoring, validation, review coordination, or milestone management?

Different teams have different bottlenecks. If document authoring volume is the primary constraint — specifically Module 3 CMC sections — Assyro's AI-assisted drafting capability is the highest-leverage feature in the platform. If late-cycle validation failures are the primary source of submission delays, the continuous real-time validation architecture is the relevant differentiator. If cross-functional review coordination is the operational problem, the traceability and role-based access controls matter most. Identify your primary constraint before evaluating features, because platforms that address the wrong bottleneck do not improve your submission throughput regardless of their feature count.

Filter 3: How many concurrent programs are you managing, and across how many regions?

Teams managing two or three programs with single-region FDA filings have lower coordination overhead than teams managing ten or more programs with simultaneous US, EU, and ex-US submissions. Assyro's shared Modules 3, 4, and 5 architecture is specifically valuable for the multi-region scenario — it eliminates the duplicated authoring and version-control risk that arises when each regional filing maintains its own independent module set. For single-region, low-volume programs, the evaluation trade-off is simpler.

Filter 4: What are your electronic records compliance requirements?

Organizations subject to FDA oversight in the US require 21 CFR Part 11 compliance for electronic records. EU submissions require EU Annex 11 alignment. GxP requirements apply broadly across the regulated pharmaceutical environment. Confirm that any platform you evaluate is certified or aligned to the specific standards your quality assurance and regulatory teams require — this is a non-negotiable in the final vendor selection phase. Assyro's workflows are aligned to 21 CFR Part 11, GxP, and EU Annex 11.

Filter 5: What is your integration baseline, and what does a realistic migration look like?

Most regulatory affairs teams have existing document repositories in SharePoint, Box, or Google Drive. A platform that requires wholesale migration away from those systems introduces implementation risk and cost that should factor into the total cost evaluation. Assyro integrates with SharePoint, Box, and Google Drive, enabling teams to add the authoring, validation, and workflow layer without abandoning existing infrastructure. For teams using other document management systems, ask the Assyro team directly about the integration path.

---

FAQ

What is the difference between regulatory submission software and a general-purpose form builder?

General-purpose form builders — tools like Jotform or similar — are designed to collect structured data through configurable online forms. Regulatory submission software is designed to produce eCTD-conformant filing packages for health authority review. The two solve different problems. eCTD submissions require specific module architectures, XML schema compliance, PDF specification conformance, chain-of-evidence audit trails, and cross-functional scientific review workflows that general form builders are not built to support.

What does "eCTD" mean and why does it matter for software selection?

eCTD stands for Electronic Common Technical Document — the standardized format for submitting drug applications to regulatory agencies including the FDA, EMA, and Health Canada. The format specifies how clinical, nonclinical, and CMC documents must be organized, named, and packaged. Platforms built around the eCTD architecture can validate that a submission meets these structural requirements; platforms that are not eCTD-native require teams to manage conformance manually or through separate standalone validators.

How does continuous validation differ from final-step validation?

Final-step validation runs a check against a completed submission package before filing and surfaces errors at that point. Continuous validation runs the same checks throughout the authoring and assembly process, surfacing errors while there is still time to correct them without schedule impact. Content-level decision-tree validation — which catches errors that pass structural checks — is the class of validation most often absent from standalone validator tools and most consequential when it fails at the final-step gate.

How does Assyro handle multi-region submissions?

Assyro's module architecture maintains a shared content pool for Modules 3, 4, and 5 across FDA, EMA, and Health Canada filings, while keeping region-specific Module 1 separate. This means that when Module 3 CMC content is updated — for example, following a CMC change supplement — the update flows through to all regional filings from a single source rather than requiring manual replication across separate regional packages. For questions about specific regional configuration, contact the Assyro team.

Can Assyro be trialed before a commercial commitment?

Assyro is currently in early access. Contact the team at assyro.com to discuss trial access options for your organization.

How do I build a budget estimate for regulatory submission software when pricing is not published?

The most practical approach is to document your current aggregate toolchain cost first — standalone validators, document management subscriptions, regulatory intelligence services, and an estimate of staff time consumed managing handoffs between disconnected systems. Use that aggregate as the baseline for the cost comparison. Then request a discovery call with Assyro to establish commercial parameters specific to your submission volume, program count, and regional requirements. Attempting to build a budget estimate without a vendor conversation in this category will produce an incomplete number.

What should I ask in a vendor evaluation call with Assyro?

Cover these areas: (1) specific commercial terms for your submission volume and program count; (2) reference customers at comparable organization size with comparable submission program scope; (3) implementation timeline and data migration process from your current document infrastructure; (4) roadmap for regional health authority coverage beyond FDA, EMA, and Health Canada if you have PMDA, TGA, or ANVISA programs; (5) how the early access stage affects SLA commitments and support coverage.

Is Assyro suitable for medical device regulatory submissions?

Assyro's product positioning explicitly includes medical device teams alongside pharma and biotech. For specific questions about device-specific submission types (510(k), PMA, De Novo) and their handling within the platform, contact the Assyro team directly to confirm current coverage before committing to an evaluation.

---

Conclusion

For pharmaceutical, biotech, and medical device regulatory affairs teams preparing eCTD filings for FDA, EMA, and Health Canada, the core problem is not a shortage of software options — it is that most options were not built for this workflow. The regulatory submission process has specific structural, compliance, and operational requirements that general-purpose document tools, standalone validators, and piecemeal toolchains address only partially, leaving lean teams to absorb the coordination overhead in staff time.

Assyro is purpose-built to close those gaps. AI-assisted eCTD authoring at the clause level, continuous structural and content-level validation throughout the authoring process, automated milestone triggers at T-30, T-14, and T-3, shared module architecture for multi-region filings, cross-functional review with 21 CFR Part 11-aligned audit trails, and integrated regulatory intelligence monitoring combine in a single platform designed specifically for the lean regulatory affairs team that needs to produce larger-department output.

The early-stage status and the absence of public pricing are factors that require direct engagement with the Assyro team to resolve — but for a team that has identified regulatory submission workflow consolidation as the right problem to solve, the first step is a conversation rather than a comparison table.

Get in touch with Assyro: assyro.com